Goldman Sachs
CAMP icon

Goldman Sachs’s CAMP4 Therapeutics CAMP Stock Holding History

Goldman Sachs’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
241,393
+163,048
+208% +$703K ﹤0.01% 5169
2026
Q1 		$346K Buy
78,345
+59,522
+316% +$283K ﹤0.01% 5816
2025
Q4 		$115K Buy
+18,823
New +$80.1K ﹤0.01% 6167
2025
Q3 		– Sell
-26,511
Closed -$38.4K – 6358
2025
Q2 		$38.4K Buy
26,511
+14,556
+122% +$29K ﹤0.01% 5940
2025
Q1 		$47.8K Sell
11,955
-5,535
-32% -$26.8K ﹤0.01% 5884
2024
Q4 		$91.3K Buy
+17,490
New +$144K ﹤0.01% 5778

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's CAMP Position: Q2 2026 in Review

Goldman Sachs increased its CAMP4 Therapeutics (CAMP) stake by 208% in Q2 2026, buying an estimated $703K and bringing the position to 241,393 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #5169.

Goldman Sachs first reported a position in CAMP in Q4 2024 and has held it in 6 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Goldman Sachs held 241,393 shares of CAMP4 Therapeutics worth $1.05M as of Q2 2026.
  • Goldman Sachs bought 163,048 CAMP4 Therapeutics shares in Q2 2026, an estimated $703K.
  • CAMP4 Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5169 holding.
  • Goldman Sachs first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.